2.4 Excretion

Excretion is a crucial process in drug elimination, involving the removal of drugs and their metabolites from the body. The main routes are renal and biliary excretion, with minor routes including sweat and saliva. Understanding these pathways is key to predicting drug behavior and interactions.

Factors like physicochemical properties, plasma protein binding, and active transport mechanisms affect excretion rates. This knowledge is essential for optimizing drug dosing, anticipating drug interactions, and minimizing side effects. Renal and biliary excretion processes involve complex mechanisms that medicinal chemists must consider in drug design.

Routes of excretion

• Excretion is the process by which the body eliminates drugs and their metabolites
• The major routes of excretion include renal excretion, biliary excretion, and other minor routes such as sweat, saliva, and breast milk
• Understanding the routes of excretion is crucial for predicting the pharmacokinetic profile and potential drug interactions of medicinal compounds

Renal excretion

Top images from around the web for Renal excretion

• 

  Physiology of the Kidneys | Boundless Anatomy and Physiology View original

  Is this image relevant?

• 

  Nephron – Structure | BIO103: Human Biology View original

  Is this image relevant?

• 

  16.4 Kidneys – Human Biology View original

  Is this image relevant?

• 

  Physiology of the Kidneys | Boundless Anatomy and Physiology View original

  Is this image relevant?

• 

  Nephron – Structure | BIO103: Human Biology View original

  Is this image relevant?

1 of 3

Top images from around the web for Renal excretion

• 

  Physiology of the Kidneys | Boundless Anatomy and Physiology View original

  Is this image relevant?

• 

  Nephron – Structure | BIO103: Human Biology View original

  Is this image relevant?

• 

  16.4 Kidneys – Human Biology View original

  Is this image relevant?

• 

  Physiology of the Kidneys | Boundless Anatomy and Physiology View original

  Is this image relevant?

• 

  Nephron – Structure | BIO103: Human Biology View original

  Is this image relevant?

1 of 3

• Renal excretion involves the elimination of drugs and their metabolites through the kidneys and into the urine
• Occurs via glomerular filtration, tubular secretion, and tubular reabsorption
• Hydrophilic and polar compounds are more likely to undergo renal excretion (acetaminophen)

Biliary excretion

• Biliary excretion involves the elimination of drugs and their metabolites through the liver and into the bile
• Occurs via hepatic uptake, biotransformation, and biliary secretion
• Lipophilic and high molecular weight compounds are more likely to undergo biliary excretion (rifampicin)

Other routes

• Minor routes of excretion include sweat, saliva, and breast milk
• These routes generally play a less significant role in drug elimination compared to renal and biliary excretion
• However, they can be important for certain drugs (alcohol in breast milk) or in specific situations (heavy sweating during exercise)

Factors affecting excretion

• Several factors can influence the rate and extent of drug excretion
• Understanding these factors is essential for optimizing drug dosing, predicting drug interactions, and minimizing adverse effects
• Key factors include physicochemical properties, plasma protein binding, and active transport mechanisms

Physicochemical properties

• Lipophilicity, molecular size, and ionization state can affect the route and rate of excretion
• Hydrophilic and polar compounds are more likely to undergo renal excretion, while lipophilic and high molecular weight compounds are more likely to undergo biliary excretion
• Ionization state can influence the extent of tubular reabsorption and secretion (weak acids and bases)

Plasma protein binding

• Drugs that are highly bound to plasma proteins (albumin) are less available for excretion
• Only the unbound fraction of the drug can undergo glomerular filtration or hepatic uptake
• Changes in plasma protein binding (disease states, drug interactions) can alter the rate of excretion

Active transport mechanisms

• Active transport mechanisms, such as transporters, can facilitate the excretion of drugs against concentration gradients
• Renal and hepatic transporters (P-glycoprotein, organic anion transporters) can significantly impact the rate and extent of excretion
• Inhibition or induction of these transporters can lead to drug interactions and altered excretion profiles

Renal excretion

• Renal excretion is a major route of elimination for many drugs and their metabolites
• Involves three main processes: glomerular filtration, tubular secretion, and tubular reabsorption
• Understanding these processes is crucial for predicting the renal clearance and potential drug interactions of medicinal compounds

Glomerular filtration

• Passive process that filters small, unbound molecules from the blood into the glomerular filtrate
• Influenced by factors such as molecular size, charge, and plasma protein binding
• Drugs that are highly bound to plasma proteins (warfarin) or have a large molecular size (heparin) are less likely to undergo glomerular filtration

Tubular secretion

• Active process that transports drugs from the blood into the tubular lumen via transporters
• Occurs primarily in the proximal tubule and can significantly enhance the renal clearance of certain drugs (metformin)
• Transporters involved in tubular secretion include organic anion transporters (OATs) and organic cation transporters (OCTs)

Tubular reabsorption

• Passive process that involves the reabsorption of drugs from the tubular lumen back into the blood
• Influenced by factors such as lipophilicity, ionization state, and urine pH
• Weak acids (aspirin) and weak bases (amphetamine) can undergo pH-dependent tubular reabsorption

Renal clearance

• Renal clearance is a measure of the efficiency of the kidneys in eliminating a drug from the body
• Calculated as the product of the glomerular filtration rate (GFR) and the fraction of the drug excreted unchanged in the urine
• Drugs with high renal clearance (gentamicin) are primarily eliminated by the kidneys, while drugs with low renal clearance (propranolol) are eliminated by other routes

Biliary excretion

• Biliary excretion is a major route of elimination for lipophilic drugs and their metabolites
• Involves several processes, including hepatic uptake, biotransformation, and biliary secretion
• Understanding these processes is essential for predicting the biliary clearance and potential drug interactions of medicinal compounds

Hepatic uptake

• Process by which drugs are taken up from the blood into the hepatocytes
• Occurs via passive diffusion or active transport mechanisms (organic anion transporting polypeptides, OATPs)
• Lipophilic and high molecular weight compounds are more likely to undergo hepatic uptake (cyclosporine)

Biotransformation

• Process by which drugs are metabolized in the liver to more hydrophilic and easily excreted compounds
• Involves phase I (oxidation, reduction, hydrolysis) and phase II (conjugation) reactions
• Biotransformation can significantly impact the biliary excretion of drugs (glucuronidation of morphine)

Biliary secretion

• Process by which drugs and their metabolites are actively transported from the hepatocytes into the bile
• Mediated by transporters such as P-glycoprotein (P-gp) and multidrug resistance-associated proteins (MRPs)
• Drugs that are substrates for these transporters (digoxin, paclitaxel) are more likely to undergo biliary secretion

Enterohepatic circulation

• Process by which drugs and their metabolites are secreted into the bile, released into the small intestine, and then reabsorbed back into the blood
• Can prolong the residence time of drugs in the body and lead to multiple peaks in the plasma concentration-time profile
• Drugs that undergo extensive enterohepatic circulation (estradiol, mycophenolic acid) may require dose adjustments or special considerations

Excretion vs elimination

• Excretion and elimination are often used interchangeably, but they have distinct meanings in pharmacokinetics
• Understanding the difference between these terms is important for accurately describing the fate of drugs in the body

Definitions

• Excretion refers to the process by which a drug or its metabolites are removed from the body via specific organs (kidneys, liver, lungs)
• Elimination is a broader term that encompasses both excretion and metabolism, referring to the overall removal of a drug from the body

Key differences

• Excretion is a subset of elimination, focusing on the removal of drugs via specific routes
• Elimination takes into account both excretion and metabolism, providing a more comprehensive view of drug removal from the body
• The elimination half-life of a drug is determined by both excretion and metabolism, while the excretion half-life only considers the excretion process

Role of transporters in excretion

• Transporters play a crucial role in the excretion of drugs and their metabolites
• They facilitate the movement of compounds across biological membranes, often against concentration gradients
• Understanding the role of transporters in excretion is essential for predicting drug interactions and optimizing drug therapy

Renal transporters

• Renal transporters are involved in the tubular secretion and reabsorption of drugs in the kidneys
• Key renal transporters include organic anion transporters (OATs), organic cation transporters (OCTs), and P-glycoprotein (P-gp)
• Inhibition or induction of these transporters can lead to altered renal excretion and potential drug interactions (probenecid and penicillins)

Hepatic transporters

• Hepatic transporters are involved in the hepatic uptake and biliary secretion of drugs in the liver
• Key hepatic transporters include organic anion transporting polypeptides (OATPs), P-glycoprotein (P-gp), and multidrug resistance-associated proteins (MRPs)
• Inhibition or induction of these transporters can lead to altered biliary excretion and potential drug interactions (rifampicin and statins)

Transporter-mediated drug interactions

• Drug interactions can occur when one drug inhibits or induces the transporters involved in the excretion of another drug
• Inhibition of transporters can lead to decreased excretion and increased exposure to the affected drug (cyclosporine and digoxin)
• Induction of transporters can lead to increased excretion and decreased exposure to the affected drug (rifampicin and methotrexate)

Excretion in drug design

• Optimizing the excretion properties of a drug is an important consideration in medicinal chemistry and drug design
• Balancing excretion with other pharmacokinetic properties (absorption, distribution, metabolism) is crucial for achieving the desired therapeutic effect and minimizing adverse effects

Optimizing excretion properties

• Strategies for optimizing excretion properties include modifying the physicochemical properties (lipophilicity, molecular size, ionization state) of a drug
• Increasing hydrophilicity can enhance renal excretion, while increasing lipophilicity can enhance biliary excretion
• Balancing excretion with other pharmacokinetic properties is essential for achieving the desired pharmacokinetic profile

Prodrugs and excretion

• Prodrugs are inactive compounds that are converted to the active drug in the body
• Designing prodrugs can be a useful strategy for optimizing the excretion properties of a drug
• Examples include ester prodrugs that increase lipophilicity and enhance biliary excretion (oseltamivir) and phosphate prodrugs that increase hydrophilicity and enhance renal excretion (fosamprenavir)

Excretion-related adverse effects

• Adverse effects can occur when drugs or their metabolites accumulate in the body due to impaired excretion
• Examples include nephrotoxicity (aminoglycosides) and hepatotoxicity (acetaminophen)
• Designing drugs with balanced excretion properties and considering the potential for excretion-related adverse effects is crucial for developing safe and effective medicines

Excretion in special populations

• Excretion can be altered in special populations, such as patients with renal or hepatic impairment and pediatric or geriatric populations
• Understanding the impact of these conditions on drug excretion is essential for optimizing drug therapy and minimizing adverse effects

Renal impairment

• Renal impairment can lead to decreased renal excretion and accumulation of drugs and their metabolites
• Dose adjustments or alternative therapies may be necessary for drugs that are primarily eliminated by the kidneys (gabapentin, levofloxacin)
• Monitoring renal function and considering the potential for drug interactions is crucial in patients with renal impairment

Hepatic impairment

• Hepatic impairment can lead to decreased biliary excretion and accumulation of drugs and their metabolites
• Dose adjustments or alternative therapies may be necessary for drugs that are primarily eliminated by the liver (warfarin, diazepam)
• Monitoring hepatic function and considering the potential for drug interactions is crucial in patients with hepatic impairment

Pediatric and geriatric populations

• Excretion can be altered in pediatric and geriatric populations due to differences in organ function and development
• Renal function and hepatic enzyme activity may be immature in pediatric patients, leading to decreased excretion
• Renal function and hepatic blood flow may decline with age in geriatric patients, leading to decreased excretion
• Dose adjustments and careful monitoring are often necessary in these populations to ensure safe and effective drug therapy

Methods to study excretion

• Various methods are used to study the excretion of drugs and their metabolites
• These methods provide valuable information for predicting the pharmacokinetic profile and potential drug interactions of medicinal compounds

In vitro models

• In vitro models, such as cell lines (Caco-2, MDCK) and isolated organs (perfused kidney, liver slices), are used to study the mechanisms of drug excretion
• These models allow for the investigation of specific transporters and metabolic pathways involved in excretion
• In vitro data can be used to predict in vivo excretion and guide the design of clinical studies

In vivo models

• In vivo models, such as animal studies (rodents, non-human primates), are used to study the excretion of drugs in a living system
• These models provide information on the overall pharmacokinetic profile and potential species differences in excretion
• In vivo data can be used to predict human pharmacokinetics and guide the design of clinical trials

Clinical studies

• Clinical studies, such as mass balance studies and pharmacokinetic studies, are used to investigate the excretion of drugs in humans
• Mass balance studies involve the administration of a radiolabeled drug and the measurement of radioactivity in urine, feces, and other matrices to determine the routes and extent of excretion
• Pharmacokinetic studies involve the measurement of drug concentrations in blood and urine to determine renal clearance and other excretion parameters

Excretion-related drug interactions

• Drug interactions can occur when the excretion of one drug is altered by another drug, leading to changes in pharmacokinetics and potentially adverse effects
• Understanding the mechanisms of excretion-related drug interactions is crucial for predicting and managing these interactions in clinical practice

Transporter-mediated interactions

• Transporter-mediated interactions occur when one drug inhibits or induces the transporters involved in the excretion of another drug
• Inhibition of renal transporters (OATs, OCTs) can lead to decreased renal excretion and increased exposure to the affected drug (probenecid and penicillins)
• Inhibition of hepatic transporters (OATPs, P-gp) can lead to decreased biliary excretion and increased exposure to the affected drug (cyclosporine and statins)

Enzyme-mediated interactions

• Enzyme-mediated interactions occur when one drug inhibits or induces the enzymes involved in the metabolism of another drug, leading to changes in excretion
• Inhibition of metabolic enzymes (CYP3A4) can lead to decreased metabolism and increased exposure to the affected drug (ketoconazole and midazolam)
• Induction of metabolic enzymes (CYP3A4) can lead to increased metabolism and decreased exposure to the affected drug (rifampicin and cyclosporine)

Altered excretion and toxicity

• Excretion-related drug interactions can lead to altered pharmacokinetics and potentially increased toxicity
• Decreased excretion can result in the accumulation of drugs and their metabolites, leading to adverse effects (lithium and NSAIDs)
• Increased excretion can result in decreased efficacy of the affected drug (oral contraceptives and rifampicin)
• Monitoring for excretion-related drug interactions and adjusting drug therapy accordingly is essential for ensuring safe and effective treatment